One-stop PROLASTIN-C enrollment, delivery and support

Prolastin Direct® Patient Services secures insurance authorization, coordinates infusion services, ships PROLASTIN-C directly to the location of your choice, and connects you to health management coordinators who are experienced Alpha-1 patients themselves. Find out more about Prolastin Direct® Patient Services now.

Insurance & Payment Support

The insurance experts at Prolastin Direct® Patient Services will coordinate appropriate insurance coverage for your PROLASTIN-C therapy. They will answer all your questions. Plus, they will work directly with your insurance company on your behalf.

99% success rate with insurance coverage1

Since Prolastin Direct® Patient Services started, our insurance experts have worked with over 1000 different insurance plans including private and government plans. They have a 99% success rate when it comes to getting coverage for PROLASTIN-C therapy.1

If you are considering PROLASTIN-C for augmentation therapy, call Prolastin Direct® Patient Services at 800-305-7881 to enroll.

Caring Voice Coalition

Caring Voice Coalition is a nonprofit organization that provides counseling and assistance with billing and reimbursement issues. For more information about all the ways that Caring Voice can help, visit www.caringvoice.org or call 888-267-1440.

Patient Services Incorporated (PSI)

PSI is a national nonprofit organization committed to helping people with chronic illnesses and conditions by assisting with premiums and co-pays. For more information about all the ways that PSI can help, visit www.uneedpsi.org or call 800-366-7741.

next: Scheduling Infusions & Delivery >

Important Safety Information
Prolastin-C, Alpha1-Proteinase Inhibitor (Human) is for adults who have emphysema caused by inherited alpha1-antitrypsin deficiency. The effect of therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

Prolastin-C may contain trace amounts of IgA. IgA deficient patients with antibodies against IgA should not receive Prolastin-C due to the risk of hypersensitivity.

The most common side effects during clinical trials with Prolastin-C were chills, a general feeling of being unwell, headache, rash, hot flush, and itching.

Prolastin-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying Prolastin-C Full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References
  1. Data on file. Centric Health Resources.